![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Awards AZ’s Selumetinib Orphan Drug Status
FDA Awards AZ’s Selumetinib Orphan Drug Status
The FDA granted orphan drug designation to AstraZeneca for its MEK1/2 inhibitor selumetinib as an adjuvant treatment in patients with stage 3 and 4 thyroid cancer.
The candidate also is being evaluated in a pivotal trial in patients suffering from KRAS-mutant advanced non-small cell lung cancer, and in a Phase 2 trial in patients with neurofibromatosis.
Upcoming Events
-
21Oct